MedTrace Logo

Stroke and Tocotrienol: Unique Role in Neuroprotection

NCT02263924 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2018-02-13

No results posted yet for this study

Summary

Phase III, single-centre, double-blind, randomised, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of oral Vitamin E (Mixed Tocotrienol) for 6 months in patients with moderate ischemic stroke.

150 patients will be recruited and randomized to receive either placebo or mixed tocotrienol 200mg twice a day for 6 months. Patients will be followed up and assessed on their functional recovery.

Conditions

Interventions

DIETARY_SUPPLEMENT

Tocotrienol

Subjects in the intervention arm will take one capsule of 200mg tocotrienol twice daily for 6 months

DIETARY_SUPPLEMENT

Placebo capsules

Subjects in the placebo arm will take one capsule of placebo twice daily for 6 months

Sponsors & Collaborators

  • Clinical Research Centre Hospital Taiping

    collaborator UNKNOWN

  • Universiti Sains Malaysia

    collaborator OTHER

  • Seberang Jaya Clinical Research Centre

    lead OTHER_GOV

Principal Investigators

  • IRENE LOOI · SEBERANG JAYA HOSPITAL CLINICAL RESEARCH CENTRE

  • KAH HAY YUEN · Universiti Sains Malaysia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02263924 on ClinicalTrials.gov